hims semaglutide results Inc Hims? Hers? It's Novo Nordisk's

Overall the results of this study, which followed over 200,000 people with diabetes who were treated with GLP1RAs and compared them to over 1.5 million people on other forms of diabetes treatment, is reassuring regarding the risk/benefit ratio for the long term use of GLP1RAs in people with diabetes

Remember: Its not just a diet

This medicine is administered into a vein by a healthcare professional and will only be given to you if your doctor thinks that an injection is more suitable for you at the moment than a tablet

Daou, N

For Crohn's patients, understanding your genetic predisposition to GLP-1 efficacy helps prescribers determine whether the expected benefit justifies gastrointestinal risks specific to your condition